IQMaxxedSubhuman
Iron
- Joined
- Jul 6, 2026
- Posts
- 239
- Reputation
- 261
Romosozumab is a humanized monoclonal antibody (marketed as Evenity) that selectively binds and neutralizes sclerostin, an osteocyte-secreted glycoprotein that serves as the body’s primary brake on the Wnt/β-catenin bone-construction pathway. By blocking sclerostin from binding to LRP5/6 co-receptors, it produces a rare dual-action effect: it triggers an aggressive surge in osteoblast proliferation and periosteal bone synthesis while simultaneously downregulating RANKL to freeze osteoclast-driven bone breakdown, resulting in rapid increases in cortical and trabecular bone mineral density (roughly 13% in the spine and 6% in the hip over a single year). In practice, it is administered as a 210 mg subcutaneous dose once per month (delivered as two simultaneous 105 mg injections) capped at a strict 12-month ceiling, after which the anabolic window plateaus due to compensatory counter-regulatory mechanisms like DKK-1 upregulation, requiring an immediate transition to an anti-resorptive agent (such as a bisphosphonate or denosumab) to stop osteoclasts from rapidly reclaiming the new unmineralized matrix. Without copes, the reality of the compound is that its bone-building action is entirely systemic rather than targeted to facial landmarks without extreme localized mechanical loading (Wolff’s Law), and because sclerostin also protects arterial walls from stiffening, the drug carries an FDA black-box warning for elevated risks of myocardial infarction, stroke, and cardiovascular death, making it an extraordinarily potent, cost-prohibitive biologic that cannot be synthesized in underground peptide labs or used casually.
